{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-026957","form_type":"8-K","ticker":null,"cik":"0001741830","company_name":"Kronos Bio, Inc.","filed_at":"2024-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.845690+00:00","generated_at":"2026-06-01T11:15:19.796913+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kronos Bio appoints Deborah Knobelman as CFO and COO effective June 3, 2024","bullets":["Deborah Knobelman appointed CFO and COO, effective June 3, 2024, replacing Sandra Gardiner.","Knobelman previously served as CFO of Senti Biosciences (SNTI) from 2021 to May 2024.","Initial base salary $475,000; target annual bonus 40% of salary; signing bonus $50,000.","Equity grants: 246,390 stock options and 164,260 RSUs with graded vesting schedules.","She will receive severance benefits under the Company’s Severance Plan for qualifying terminations."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-026957","json":"https://secwatch.observer/filing/0001140361-24-026957.json","markdown":"https://secwatch.observer/filing/0001140361-24-026957.md","text":"https://secwatch.observer/filing/0001140361-24-026957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1741830/000114036124026957/0001140361-24-026957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1741830/000114036124026957/ef20029602_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T11:15:19.796913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55bdfd62ae","claim":"Deborah Knobelman was appointed as Chief Financial Officer and Chief Operations Officer at Kronos Bio, Inc..","evidence_excerpt":"On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000114036124026957/0001140361-24-026957-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Chief Operations Officer"}],"fact_type":"executive_change"},{"claim_id":"ec3f4ae2f3","claim":"Sandra Gardiner departed as Chief Financial Officer at Kronos Bio, Inc..","evidence_excerpt":"On May 20, 2024, the board of directors of Kronos Bio, Inc. (the “Company”) appointed Deborah Knobelman, Ph.D. as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, replacing Sandra Gardiner in such capacities, and as the Company’s Chief Operations Officer, with such appointments to be effective on June 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000114036124026957/0001140361-24-026957-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}